安科生物：参股公司PA3-17注射液获准进入关键性II期临床试验 为全球首款获得新药临床试验批准的靶向CD7的自体CAR-T细胞治疗产品

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received approval from the National Medical Products Administration for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy product for treating adult relapsed and refractory CD7-positive hematological malignancies [1]. Group 1 - Anke Biotech's affiliated companies have received a communication meeting minutes from the National Medical Products Administration regarding the PA3-17 injection [1]. - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product that has received approval for clinical trials [1]. - The product is specifically designed for the treatment of adult patients with relapsed and refractory CD7-positive hematological malignancies [1].